Sanofi to acquire Inhibrx-101 for around $2.2B



French pharmaceutical company Sanofi S.A. announced in a written statement on Tuesday its decision to acquire Inhibrx-101, an Inhibrx Inc. drug development project, for around $2.2 billion.

According…